https://www.selleckchem.com/pr....oducts/pirtobrutinib
Clinical trials investigating HDACi to reverse HIV-1 latency aim to expose reservoirs in antiretroviral-treated individuals to clearance by immune effectors, yet have not driven measurable reductions in the frequencies of infected cells. We therefore investigated the effects of the class-I-selective HDACi nanatinostat and romidepsin on various blocks to latency reversal and elimination, including viral splicing, antigen presentation, and CD8+ T cell function. In ex vivo CD4+ T cells from ARV-suppressed individuals, both H
Like
Comment
Share
